贝达药业：CFT8919项目目前在临床Ⅰ期研究中

Core Insights - Betta Pharmaceuticals is advancing its BPI-572270 project, a molecular glue inhibitor, and is preparing to submit an Investigational New Drug (IND) application [1] - The CFT8919 project, an orally bioavailable allosteric BiDAC™ degrader, is currently in Phase I clinical trials [1]